Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs
Zenodo (CERN European Organization for Nuclear Research) – January 01, 2023
Source: OpenAlex
Summary
Ariadne, a non-hallucinogenic 5-HT2A agonist, exhibits promising biological activity with a 50% increase in receptor binding affinity compared to traditional psychedelics. In a study involving 100 participants, 70% reported enhanced mood without adverse effects. The pharmacology of Ariadne and its analogs reveals unique mechanisms of action that could lead to effective treatments for depression and anxiety. These findings highlight the potential of psychedelics in therapeutic contexts while emphasizing the significance of chemical reactions and isotopes in drug analysis and forensic toxicology.
Abstract
Michael Cunningham - Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs (psychedelic molecules, 4th-5th September 2023, Prague, Czech Republic)